New Jersey Managed Markets Solutions Provider Delivers Dynamic Business Solutions With Their New Data Suite Application

Monday, May 10, 2010 News on IT in Healthcare J E 4

MOUNT OLIVE, N.J., May 10 Pinsonault Associates has enhanced their proprietary software application, Today's Accounts. The augmentation creates a new enterprise level, Web-based, managed markets integrated dashboard application called PathfinderRx. This multi-dimensional software tool embodies advanced capabilities for those seeking to create and/or improve sales strategies and tactics by providing in-depth market share, formulary, and analytical data. The data can be massaged in a variety of ways, from creating pull-through campaigns to creating targeted messaging to creating comprehensive account profiles. The customizable reporting features allow for the creation of virtually a limitless number of reporting options, which can be tailored to the specific needs of any client, providing granular results that lead to improved sales planning and success. The application also contains an on-the-spot training tool, for users looking to improve their sales knowledge and technique.

Pinsonault Associates is dedicated to and focused on delivering high quality, managed markets specific, business and training solutions within the pharmaceutical and biotech industries. From content development and data management to Web-based applications, Pinsonault Associates is a multi-faceted business solution provider, possessing the knowledge and expertise to provide pharmaceutical and biotech companies with leadership in health care communications and sales training initiatives. Pinsonault's mission requires a commitment to quality, excellence, and integrity in all of their service offerings.

For more information on Pinsonault Associates, visit

Pinsonault Associates, LLC 350 Clark Drive Mount Olive, NJ 07828 Ph: 973-448-8800 Toll free: 800-372-9009 Fax: 973-448-1005

SOURCE Pinsonault Associates, LLC


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
VIVUS To Present at Four Upcoming Investor Confere...
For Emerging Therapies in the Treatment of Hepatit...